These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 24840612

  • 1. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U, Ekman M, Granström O, Bergenheim K, McEwan P.
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
    Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.
    BMC Health Serv Res; 2015 Nov 05; 15():496. PubMed ID: 26541516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H, Zhai S, Zou D, Mir MU, Zawadzki NK, Shi Q, Liu S, Shi L.
    Curr Med Res Opin; 2017 Feb 05; 33(2):359-369. PubMed ID: 27817216
    [Abstract] [Full Text] [Related]

  • 7. Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
    Elsisi GH, Anwar MM, Khattab M, Elebrashy I, Wafa A, Elhadad H, Awad M, Carapinha JL.
    J Med Econ; 2020 Aug 05; 23(8):908-914. PubMed ID: 32364032
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S, Deng J, Shi L, Mu Y, Dong H.
    J Med Econ; 2015 Aug 05; 18(10):808-20. PubMed ID: 25950193
    [Abstract] [Full Text] [Related]

  • 9. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A, Rastogi M, Dhankhar P, Bell KF.
    J Med Econ; 2018 May 05; 21(5):497-509. PubMed ID: 29376760
    [Abstract] [Full Text] [Related]

  • 10. [Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain].
    Abad Paniagua EJ, Casado Escribano P, Fernández Rodriguez JM, Morales Escobar FJ, Betegón Nicolás L, Sánchez-Covisa J, Brosa M.
    Aten Primaria; 2015 Oct 05; 47(8):505-13. PubMed ID: 25555492
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.
    Van der Linden N, Van Olst S, Nekeman S, Uyl-de Groot CA.
    Diabet Med; 2021 Apr 05; 38(4):e14371. PubMed ID: 32745279
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL, Ofori-Asenso R, Si S, Hird TR, Magliano DJ, Zoungas S, Liew D.
    Sci Rep; 2019 Mar 01; 9(1):3256. PubMed ID: 30824788
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M.
    Clin Drug Investig; 2014 Feb 01; 34(2):135-46. PubMed ID: 24243529
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct 01; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.